Original news and analysis on international IP policy
The United States Patent and Trademark Office (USPTO) today published final rules of practice implementing the "first-inventor-to-file" provision of the Leahy-Smith America Invents Act (AIA). This comes just days after a change in patent fees.
Alongside the World Intellectual Property Organization meeting on protection of genetic resources last week, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) organised a side event on natural product research.
At the World Intellectual Property Organization meeting on protection of genetic resources last week, the secretariat of the UN Convention on Biological Diversity (CBD) organised a side event to introduce the key features and recent developments of the international protocol on access and benefit-sharing of such resources.
In the annual state of the union speech, newly re-elected US President Obama outlined numerous initiatives aimed at strengthening the United States inwardly, but he also kept his eye on international competitiveness. For instance, he called for a massive increase in research and development, as well as a focus on education and skills, manufacturing, science and innovation, and international trade agreements with Asia and Europe.
The European Parliament last week overwhelmingly adopted a text on transparency that was said to improve conditions for generic medicines in the region. The voting documents are now available.
A new quarterly report on patent sales by technology shows that in 2012 the median price paid for issued US patents was US$ 221,000, while the average price paid was US$ 374,000.
The United Kingdom Intellectual Property Office has appointed its fourth IP attaché, this time to represent UK businesses in the 10 countries that make up the Association of Southeast Asian Nations (ASEAN).
Intellectual Ventures, a patent holding company, has filed a patent infringement suit against DSL providers AT&T, CenturyLink and Windstream Communications.
A 2011 letter from the top Republican on the United States Senate Finance Committee condemned efforts by the Global Fund to train public health officials on the use of flexibilities to the patent system contained in international trade rules. The letter, which also attacked the purchase of generic medicines over brand-name drugs, came just months before the US helped remove the head of the Global Fund, ultimately replacing him with an American official.
The coming year promises to be very interesting at the intersection of intellectual property with biotechnology and biodiversity. Patentability of human genes in the United States, of conventionally bred plants in Europe, plant breeders' rights and the management of regulatory authorisations when patents on genetic traits expire, the future of genetically modified organisms in developing countries, and the usual resistance they are meeting from civil society and famers' groups are some of the issues that will continue to feed debates – and potentially create opportunities - in 2013.